The company manufactures and installs fiber-reinforced polymer (FRP) products like doors and frames, alongside providing wastewater treatment solutions such as bio-digester toilets and sewage treatment plants for industrial and residential clients.
The company claims a moat through DRDO-licensed technology for bio-digesters and a leading regional position in FRP doors. However, the quantitative snapshot shows EPS CAGR is negative (-6.9%) despite high revenue growth, and cash conversion is deeply negative (-0.89), suggesting the technology does not yet translate into durable pricing power or cash-flow dominance.
Capital has been primarily directed toward working capital and the acquisition of manufacturing assets from a promoter-owned entity. While ROCE is high, the negative cash conversion indicates that significant capital is being trapped in trade receivables rather than generating free cash flow.
The business collapsed because it was never actually a business, but a cash-trapping mechanism for the benefit of its promoters. Despite growing revenue, the company failed to collect its dues, with trade receivables ballooning until they were eventually written off as uncollectible. The capital supposedly earned was diverted into related-party land deals and asset purchases from insiders, leaving the company insolvent when credit tightened. The revolving door of executives was the final warning that the internal controls were a fiction, and the licensed technology proved to have no pricing power in a commoditized market.
RichFakir rates EP Biocomposites Ltd's business quality as decent — 55/100 on our quality score (profitability, growth, balance-sheet strength and capital allocation). We assess its competitive moat as narrow.
On our model, EP Biocomposites Ltd is trading about 8% below our estimate of fair value; we rate its price fair. This is an educational estimate from public filings, not a recommendation.
RichFakir's educational verdict on EP Biocomposites Ltd is: Avoid. We are steering clear of this one — the red flags below outweigh anything the price or numbers offer.
RichFakir's educational estimate of EP Biocomposites Ltd's fair value is about ₹98 per share, derived from public filings. It's our estimate for research — not a price target or a recommendation to buy or sell.
View the full live analysis →